IDH1 and neoplasm: Consensus has been reached that EGFR amplification or combined complete + 7/ − 10 chromosome signature or TERT promoter mutation constitute the minimal molecular criteria for identifying an aggressive IDH wt diffuse astrocytic glioma whose clinical course would follow that of an IDH wt grade 4 tumor, despite appearing histologically as a WHO grade II or III [1].